Type 1 diabetes (T1D) affects roughly 9.5 million people globally, and for most of the disease’s history, clinical development has focused on improving insulin delivery, glucose monitoring, and glycemic control. That paradigm is shifting rapidly. Scientific advances have moved the field beyond disease management toward disease-modifying therapies, beta-cell replacement strategies, immune interventions, and cure-directed approaches. This is collectively reshaping endpoints, target populations, safety considerations, and regulatory expectations along the way. For biotech and emerging biopharma companies, the greatest challenges are no longer scientific feasibility but operational execution and moving from an early-stage program to regulatory approval demands expert-level understanding of the science, the evolving clinical landscape, and the operational factors that determine success.
Read the full article to learn about:
Authors:
